Cullinan Therapeutics (CGEM) News Today $8.61 -0.34 (-3.80%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$8.65 +0.04 (+0.52%) As of 06/13/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CGEM Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Consensus Rating of "Buy" from AnalystsJune 14 at 3:45 AM | americanbankingnews.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Average Rating of "Buy" by BrokeragesCullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) has been assigned a consensus recommendation of "Buy" from the five research firms that are covering the firm, Marketbeat reports. Five equities research analysts have rated the stock with a buy recommendation. The average 12-month priceJune 14 at 3:44 AM | marketbeat.comStifel Nicolaus Begins Coverage on Cullinan Therapeutics (NASDAQ:CGEM)June 13 at 2:38 AM | americanbankingnews.comCullinan Therapeutics (NASDAQ:CGEM) Coverage Initiated at Stifel NicolausStifel Nicolaus began coverage on shares of Cullinan Therapeutics in a research note on Wednesday. They issued a "buy" rating and a $22.00 price objective for the company.June 11, 2025 | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Shares Down 4.7% - Time to Sell?Cullinan Therapeutics (NASDAQ:CGEM) Trading Down 4.7% - What's Next?June 5, 2025 | marketbeat.comCullinan Therapeutics Nabs Licensing Rights to Myeloma TreatmentJune 4, 2025 | marketwatch.comCullinan Therapeutics in-pact with Genrix Bio for velinotamigJune 4, 2025 | msn.comCullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune DiseasesJune 4, 2025 | globenewswire.comBank of America Corp DE Cuts Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)Bank of America Corp DE trimmed its position in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) by 62.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 155,270 shares of the company's stock after selling 254,523 shares during tJune 4, 2025 | marketbeat.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Sees Significant Decline in Short InterestCullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) was the recipient of a significant drop in short interest during the month of May. As of May 15th, there was short interest totalling 5,990,000 shares, a drop of 19.9% from the April 30th total of 7,480,000 shares. Approximately 16.7% of the company's stock are short sold. Based on an average daily trading volume, of 460,500 shares, the days-to-cover ratio is currently 13.0 days.June 2, 2025 | marketbeat.comTaiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical OncologyJune 1, 2025 | prnewswire.comCullinan Therapeutics (NASDAQ:CGEM) Stock Price Up 9.2% - Here's WhyCullinan Therapeutics (NASDAQ:CGEM) Trading Up 9.2% - What's Next?May 30, 2025 | marketbeat.comCullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare ConferenceMay 29, 2025 | globenewswire.comWoodline Partners LP Makes New $2.04 Million Investment in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)Woodline Partners LP bought a new position in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 167,315 shares of the company's stock, valued at approximately $2,038,000.May 27, 2025 | marketbeat.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Acquired by Millennium Management LLCMillennium Management LLC increased its position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) by 5.8% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 833,962 shares of the company's stock after purchasing an additional 45,May 26, 2025 | marketbeat.comAmeriprise Financial Inc. Raises Stake in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)Ameriprise Financial Inc. raised its position in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) by 20.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 504,264 shares of the compMay 26, 2025 | marketbeat.comCullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025May 22, 2025 | globenewswire.com115,000 Shares in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Acquired by BNP Paribas Financial MarketsBNP Paribas Financial Markets acquired a new position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 115,000 shares of the company's stock, valued at approximately $1,401,000. BNPMay 22, 2025 | marketbeat.comPatient Square Capital LP Has $10.71 Million Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)Patient Square Capital LP grew its holdings in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) by 6.6% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 878,897 shares of the company's stock after buying an additional 54May 16, 2025 | marketbeat.comCullinan Therapeutics (CGEM) Projected to Announce Quarterly Earnings on WednesdayCullinan Therapeutics (NASDAQ:CGEM) will be releasing its Q1 2025 earnings before the market opens on Wednesday, May 21. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-21-cullinan-management-inc-stock/)May 16, 2025 | marketbeat.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Position Raised by Orbimed Advisors LLCOrbimed Advisors LLC lifted its position in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) by 81.5% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 1,942,555 shares of the company's stock after acquiring an additional 872,500 shares duringMay 15, 2025 | marketbeat.comCubist Systematic Strategies LLC Acquires New Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)Cubist Systematic Strategies LLC purchased a new stake in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 130,647 shares of the company's stMay 15, 2025 | marketbeat.comUBS Group Cuts Cullinan Therapeutics (NASDAQ:CGEM) Price Target to $24.00UBS Group decreased their price objective on Cullinan Therapeutics from $30.00 to $24.00 and set a "buy" rating on the stock in a report on Monday.May 14, 2025 | marketbeat.comDimensional Fund Advisors LP Acquires 295,467 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM)Dimensional Fund Advisors LP grew its stake in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) by 28.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,318,372 shares of the comMay 11, 2025 | marketbeat.comDeerfield Management Company L.P. Series C Boosts Stock Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)Deerfield Management Company L.P. Series C grew its holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) by 3.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,379,399 shares of the company's stock after purchasing an adMay 10, 2025 | marketbeat.comCullinan Therapeutics reports Q1 EPS (74c), consensus (81c)May 9, 2025 | msn.comCullinan Therapeutics: Q1 Earnings SnapshotMay 8, 2025 | sfgate.comCullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial ResultsMay 8, 2025 | globenewswire.comBoxer Capital Management LLC Invests $11.06 Million in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)Boxer Capital Management LLC purchased a new stake in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 907,895 shares of the company's stock, valueMay 4, 2025 | marketbeat.comQ1 EPS Forecast for Cullinan Therapeutics Raised by AnalystCullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) - Equities research analysts at Leerink Partnrs increased their Q1 2025 EPS estimates for shares of Cullinan Therapeutics in a report issued on Monday, April 28th. Leerink Partnrs analyst A. Berens now forecasts that the company will post eaMay 3, 2025 | marketbeat.comCullinan Therapeutics to begin US trial of CLN-978 to treat Sjögren’s diseaseApril 30, 2025 | msn.com634,558 Shares in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Bought by Foresite Capital Management VI LLCForesite Capital Management VI LLC acquired a new stake in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 634,558 shares of the compaApril 30, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Has $12.55 Million Stock Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)Adage Capital Partners GP L.L.C. lessened its stake in Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) by 24.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,030,438 shares of the company's stockApril 30, 2025 | marketbeat.comLynx1 Capital Management LP Buys 846,965 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM)Lynx1 Capital Management LP raised its position in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) by 206.2% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 1,257,795 shares of the company's stock after purchasing an additional 846,965 shareApril 29, 2025 | marketbeat.comCullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjögren's Disease in the United StatesApril 29, 2025 | globenewswire.comRenaissance Technologies LLC Sells 91,292 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM)Renaissance Technologies LLC decreased its stake in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) by 32.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 190,508 shares of the company's stock after selling 91,292 shares during the periodApril 28, 2025 | marketbeat.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Average Rating of "Buy" from BrokeragesCullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) has earned a consensus recommendation of "Buy" from the six analysts that are covering the stock, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy rating. The average 1-year target price among analysts tApril 28, 2025 | marketbeat.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Bought by Blue Owl Capital Holdings LPBlue Owl Capital Holdings LP lifted its stake in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) by 17.9% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,370,972 shares of the company's stock after acquApril 26, 2025 | marketbeat.comJPMorgan Chase & Co. Buys 169,104 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM)JPMorgan Chase & Co. boosted its stake in Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) by 580.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 198,214 shares of the company's stock after purchasing an additionalApril 26, 2025 | marketbeat.comMarshall Wace LLP Sells 402,071 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM)Marshall Wace LLP reduced its holdings in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) by 38.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 651,693 shares of the company's stockApril 25, 2025 | marketbeat.comJump Financial LLC Has $806,000 Stock Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)Jump Financial LLC raised its holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) by 130.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 66,135 shares of the company's stock after buying an additional 37,469 shares durinApril 24, 2025 | marketbeat.comCullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025April 23, 2025 | globenewswire.comVoss Capital LP Makes New Investment in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)Voss Capital LP bought a new stake in Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 122,361 shares of the company's stock, valued at approximately $1,490,000. Voss Capital LP ownedApril 23, 2025 | marketbeat.com43,399 Shares in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Purchased by XTX Topco LtdXTX Topco Ltd bought a new stake in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 43,399 shares of the company's stock, valued at approximatApril 22, 2025 | marketbeat.comWalleye Capital LLC Decreases Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)Walleye Capital LLC decreased its position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) by 52.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 156,497 shares of the company's stock after selliApril 21, 2025 | marketbeat.comCullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in ...April 18, 2025 | seekingalpha.comCullinan Therapeutics' (CGEM) Buy Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $33.00 price objective on shares of Cullinan Therapeutics in a report on Wednesday.April 18, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Hyperfine (HYPR) and Cullinan Management (CGEM)April 17, 2025 | markets.businessinsider.comCullinan receives approval from EMA to initiate Phase 1 trial of CLN-978April 17, 2025 | markets.businessinsider.comKennedy Capital Management LLC Invests $1.35 Million in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)Kennedy Capital Management LLC acquired a new position in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 111,049 sApril 17, 2025 | marketbeat.com Get Cullinan Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGEM and its competitors with MarketBeat's FREE daily newsletter. Email Address CGEM Media Mentions By Week CGEM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CGEM News Sentiment▼0.800.90▲Average Medical News Sentiment CGEM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CGEM Articles This Week▼63▲CGEM Articles Average Week Get Cullinan Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGEM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CGON News HRMY News TWST News BLTE News AGIO News IDYA News SDGR News INDV News GLPG News APGE News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CGEM) was last updated on 6/16/2025 by MarketBeat.com Staff From Our PartnersAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredBillionaires are piling into this gold investmentBillionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scra...Weiss Ratings | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cullinan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cullinan Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
